capravirine
Small moleculeexperimental
Capravirine was a non-nucleoside reverse transcriptase inhibitor which reached phase II trials before development was discontinued by Pfizer. Both phase IIb trials which were conducted failed to demonstrate that therapy with capravirine provided any significant advantage over existing triple-drug HIV therapies, and pharmacology studies showed that capravirine may interact with other HIV drugs. — Wikipedia
Clinical trial activity
9 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
6
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 1999 (NCT00004999)
Timeline
Indications
Mechanism of action
- Reverse transcriptaseINHIBITOR
Reverse transcriptase inhibitor
Human immunodeficiency virus type 1 reverse transcriptase inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)c1nc(COC(N)=O)n(Cc2ccncc2)c1Sc1cc(Cl)cc(Cl)c1- Mol. weight
- 451.38 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaCapravirine ↗
- ChEMBLCHEMBL435128 ↗
Also known as
- (5-(3,5-dichlorophenyl)sulfanyl-4-propan-2-yl-1-(pyridin-4-ylmethyl)imidazol-2-yl)methyl aminoformate
- 5-(3,5-dichlorophenyl)thio-4-isopropyl-1-(4-pyridyl)methyl-1h-imidazol-2-ylmethyl carbamate
- ag-1549
- capravirine
- capravirine
- capravirine
- capravirine
- capravirine
- s1153
- s 1153
- s-1153
- s-1153
- s-1153
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00052117 | Phase 2 | Jan 1, 2003 | Pfizer |
| NCT00051844 | Phase 2 | Aug 1, 2002 | Pfizer |
| NCT00006519 | Phase 1 | Nov 1, 2000 | National Cancer Institute (NCI) |
| NCT00005673 | Phase 1 | May 1, 2000 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00006211 | Phase 2 | Feb 1, 2000 | Agouron |
| NCT00004985 | Phase 2 | Jan 1, 2000 | Agouron |
| NCT00002214 | Phase 1 | Nov 2, 1999 | Lexigen Pharmaceuticals |
| NCT00004998 | Phase 2 | Nov 1, 1999 | Agouron |
| NCT00004999 | Phase 2 | Aug 1, 1999 | Agouron |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Agouron | For profit | 4 | 4 | 1 | 1999 |
| Pfizer | For profit | 2 | 2 | 1 | 2002 |
| Lexigen Pharmaceuticals | For profit | 1 | 1 | 1 | 1999 |
| National Cancer Institute (NCI) | Government | 1 | 1 | 1 | 2000 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 1 | 1 | 2000 |
5 organizations
Page 1 / 1